Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15378778 | 0.90 | DPP4 (0.47) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL15378779 | 0.90 | DPP4 (0.47) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL17309195 | 0.90 | DPP4 (0.47) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL18890084 | 0.88 | DPP4 (0.46) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL17295980 | 0.88 | DPP4 (0.46) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL14094520 | 0.82 | NPC1 (0.52) | MEN1TSHRKMT2ARIPK1SLC6A7 | |
| SCHEMBL3715603 | 0.82 | RIPK1 (0.48) | RIPK1DPP4DPP8DPP9SLC6A7 | |
| SCHEMBL15378530 | 0.81 | DPP4 (0.40) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL31357446 | 0.81 | RIPK1 (0.43) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL23515334 | 0.80 | PRKCQ (0.49) | PRKCQDPP4DPP8DPP9IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4169575-B1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMA (JP) | 2026-01-07 | — | — | EP | disclosed |
| CN-115667259-B | Fused ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2025-06-17 | — | — | CN | disclosed |
| CN-119768169-A | Substituted fused bicyclic compounds and related methods of treatment | 阿尔克姆斯有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119730843-A | Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment | 阿尔克姆斯有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-4169575-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
| US-20230107941-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-06 | — | — | US | disclosed |
| CN-115667259-A | Condensed ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| US-11254666-B2 | Compound as GLS1 inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-02-22 | — | — | US | disclosed |
| EP-3640250-B1 | COMPOUND AS GLS1 INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2021-12-15 | — | — | EP | disclosed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-2129660-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | Pfizer Products Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107941-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | HTR3E 4400/4885MEN1 4740/4885HTR3B 3619/4885 |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | HTR3E 3420/4885MEN1 4332/4885HTR3B 2891/4885 |
| US-11254666-B2 | Compound as GLS1 inhibitor | GLS, GLS2, GLB1 | HTR3E 4136/4885MEN1 1943/4885HTR3B 3387/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HTR3E 2553/4885MEN1 2003/4885HTR3B 1914/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | HTR3E 1127/4885MEN1 4367/4885HTR3B 1360/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | HTR3E 3420/4885MEN1 4332/4885HTR3B 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.